Alnylam Pharmaceuticals Inc
$ 219.20
1.43%
07 Aug - close price
- Market Cap 29,330,958,000 USD
- Current Price $ 219.20
- High / Low $ 219.64 / 210.49
- Stock P/E 37.60
- Book Value 10.12
- EPS 5.83
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.12 %
- ROE 0.97 %
- 52 Week High 495.55
- 52 Week Low 197.81
About
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$375.76
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-04-30 | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 |
| Reported EPS | 1.21 | 1.99 | 1.25 | 2.9 | 0.32 | -0.01 | 0.06 | -0.5 | 0.56 | -0.16 | -0.77 | 1.74 |
| Estimated EPS | 1.44 | 1.47 | 1.5 | 1.75 | 0.15 | -0.37 | -0.14 | -0.39 | -0.69 | -0.63 | -0.77 | -0.96 |
| Surprise | -0.23 | 0.52 | -0.25 | 1.15 | 0.17 | 0.36 | 0.2 | -0.11 | 1.25 | 0.47 | 0 | 2.7 |
| Surprise Percentage | -15.9722% | 35.3741% | -16.6667% | 65.7143% | 113.3333% | 97.2973% | 142.8571% | -28.2051% | 181.1594% | 74.6032% | 0% | 281.25% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALNY
2026-08-06 19:11:30
This article provides a comprehensive overview of Alnylam Pharmaceuticals, Inc. (ALNY), including its current stock price, recent performance metrics, and key financial data. It details the company's various therapeutic products, both commercialized and in different phases of clinical trials, focusing on its RNA interference-based treatments. The report also highlights analyst ratings, valuation measures, and comparative performance against competitors within the biotechnology sector.
2026-08-06 14:10:36
Alnylam Pharmaceuticals (ALNY) experienced a significant intraday share price drop following lowered 2026 TTR product sales guidance, despite strong quarterly revenues. The company's stock has been under pressure for much of 2026, yet analysts maintain a consensus price target of $434.72, suggesting it is 47.4% undervalued. However, the valuation hinges on successful Amvuttra execution and stable pricing, with sensitivity to any setbacks in the TTR franchise.
2026-08-06 14:10:36
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) following a significant drop in its stock price. This investigation stems from Alnylam lowering its full-year 2026 TTR product sales guidance by approximately $200 million, leading to a 28.35% intraday stock drop on July 30, 2026. The firm encourages Alnylam stockholders to connect to assist in the investigation.
2026-08-06 12:10:36
Implied volatility for Alnylam Pharmaceuticals (ALNY) stock options is surging, particularly for the Sep 18, 2026 $170 Call, indicating that the market expects a significant price movement. Despite this, analysts currently rate Alnylam Pharmaceuticals as a Zacks Rank #3 (Hold), with recent downward revisions to earnings estimates, suggesting potential trading opportunities for options traders. This high implied volatility could be attractive for options traders looking to sell premium.
2026-08-05 18:05:09
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance, leading to a significant drop in its stock price. The firm is encouraging investors who purchased Alnylam securities to contact them to learn more and assist with the investigation. The investigation stems from Alnylam's announcement on July 30, 2026, where it reduced projected TTR net product revenues by approximately $200 million due to evolving market conditions.
2026-08-04 19:10:02
Bragar Eagel & Squire, P.C. is investigating potential claims against Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of its stockholders. This investigation follows Alnylam's announcement of lowered TTR product sales guidance for full-year 2026, leading to a significant drop in its stock price. Investors who suffered losses are encouraged to contact the firm to discuss their legal rights.
